For Immediate Release
Chicago, IL – March 31, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Inc. (
UNH Quick Quote UNH - Free Report) , Johnson & Johnson ( JNJ Quick Quote JNJ - Free Report) , Alibaba Group Holding Ltd. ( BABA Quick Quote BABA - Free Report) , Oracle Corp. ( ORCL Quick Quote ORCL - Free Report) and Nike, Inc. ( NKE Quick Quote NKE - Free Report) . Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for UnitedHealth, Johnson & Johnson and Alibaba
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Johnson & Johnson, and Alibaba Group Holding Ltd. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>> UnitedHealth shares have gained +39.1% over the past year against the Zacks Medical - HMOs industry's gain of +34.4%. The Zacks analyst believes that the company's top line has been growing and the momentum should continue in the years ahead on the back of a strong market position and an attractive core business that continues to be driven by new deals, renewed agreements and expansion of service offerings.
Its solid health services segment, which is on track to bulk up with the recently announced LHC group purchase, provides diversification benefits. The firm's government business remains well-poised for growth.
A sturdy balance sheet and solid cash generation abilities enable investments and prudent capital deployment through share buybacks and dividends. However, softness in commercial business due to the COVID-induced volatilities persists. Also, rising operating costs are hurting its profits.
) read the full research report on UnitedHealth here >>> Johnson & Johnson shares have gained +4.5% over the year to date period as against the Zacks Large Cap Pharmaceuticals industry's gain of +4.1%. The Zacks analyst believes that the pharma unit is performing at above-market levels, supported by its blockbuster drugs, Darzalex and Stelara and contribution from newer drugs, Erleada and Tremfya and its COVID-19 vaccine. Sales in the Consumer unit are improving, withstanding external supply constraints.
J&J is making rapid progress with its pipeline and line extensions. Several pivotal data readouts are expected in 2022. However, the Medical Devices segment is being hurt by softening of recovery trends in medical and surgical procedures. Headwinds like generic competition and pricing pressure continue. Though J&J has taken meaningful steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.
) read the full research report on Johnson & Johnson here >>> Alibaba shares have declined -1.8% over the year to date period as against the Zacks Internet - Commerce industry's decline of -3.2%. The Zacks analyst believes that the increasing investments might hurt its profitability. Rising expenses associated with new initiatives remain overhang.
It also continues to face growing competition from domestic as well as foreign e-commerce companies despite its strong e-commerce platform. Intensifying competition in the cloud market does not bode well for its initiatives toward global expansion. Furthermore, the company's increasing regulatory concerns in China are headwinds.
However, the company's New Retail strategy which is gaining momentum in the market is acting as a tailwind. This is aiding growth in Tmall Import, Freshippo and Intime Department Stores. Furthermore, well-performing Cainiao logistics services are contributing well.
) read the full research report on Alibaba here >>>
Other noteworthy reports we are featuring today include Oracle Corp. and Nike, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. https://www.zacks.com/performance